Banyu/Merck’s Cervical Cancer Vaccine Gardasil Receives WHO Prequalification
This article was originally published in PharmAsia News
Executive Summary
Merck Japanese subsidiary Banyu Pharmaceutical June 4 announced that human papillomavirus quadrivalent vaccine Gardasil obtained World Health Organization prequalification, which recognizes the efficacy and safety of the vaccine and enables United Nation agencies to purchase the vaccine for immunization purposes. Gardasil is approved in 111 countries and has not yet been approved in Japan. The prequalification could help the drug obtain faster Japanese approval. (Click here for more - Japanese language